Adrian L. Rabinowicz, M.D., FAAN Joins Sancilio Pharma As CMO

RIVIERA BEACH, Fla.--(BUSINESS WIRE)--Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced that Adrian L. Rabinowicz, M.D., FAAN, has joined SPCI as Chief Medical Officer.

Adrian L. Rabinowicz, M.D., FAAN, has joined Sancilio Pharmaceuticals Company, Inc. (SPCI) as Chief Medical Officer, reporting to Dr. Frederick Sancilio, Chief Executive Officer. Dr. Rabinowicz will have responsibility for SPCI’s clinical development, clinical strategy and operational activities to advance the company’s pipeline.

Before joining Sancilio Pharmaceuticals, Dr. Rabinowicz spent over 18 years in different global pharmaceutical and biotechnology companies, holding roles of increasing responsibility covering clinical development and medical affairs in a variety of therapeutic areas and was involved in numerous NDA submissions. Most recently, Dr. Rabinowicz was Senior Vice President Clinical Development and Medical Affairs at Acorda Therapeutics, a publicly traded company, where he was responsible for helping progress their late stage CNS programs and preparing the medical affairs department to support future product launches, while also interacting with regulatory authorities. He also served as an active member of Acorda’s different committees responsible for ensuring medical governance as well as evaluating key in-licensing opportunities.

Dr. Rabinowicz received his medical degree from the Universidad Del Salvador, Buenos Aires, Argentina. He completed his residency in neurology at the University of Buenos Aires and his fellowship in Epilepsy and Neurophysiology at the University of Southern California, Los Angeles. Dr. Rabinowicz is Board Certified in Neurology and, for several years, served as both an Assistant Professor of Neurology and the Co-Director of the USC Comprehensive Epilepsy program, a selected NINDS site for antiepileptic drug development. Subsequently, Dr. Rabinowicz helped establish the Comprehensive Epilepsy Program at the Fleni Neurological Institute in Buenos Aires, Argentina. This program has become an international referral center for patients with refractory epilepsy as well as a leading institution for the clinical development of antiepileptic drugs. Dr. Rabinowicz has received several national and international awards for his research, is a Fellow of the American Academy of Neurology, and has published over 75 peer-reviewed papers and several book chapters.

About Sancilio Pharmaceuticals Company, Inc.

Sancilio Pharmaceuticals Company, Inc. (SPCI) is a fully integrated, specialty pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products, including those based on our proprietary Advanced Lipid Technologies™ (ALT™) platform. SPCI is pursuing treatments for sickle cell disease, short bowel syndrome and severe hypertriglyceridemia. We utilize our cGMP compliant facility to develop and manufacture our products. Our ALT™ platform is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs). Lipids are hydrophobic or amphipathic molecules, including fatty acids, steroids (including hormones) and fat-soluble vitamins (such as vitamins A, D, E and K). Our business model is to apply our ALT™ platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases resulting from imbalances of lipids in the body. In addition to our primary focus of developing our proprietary products using the ALT™ platform, we make use of, and license rights to, our proprietary ALT™ platform and other technologies to third parties, providing both development and subsequent soft gelatin encapsulation services as required. More information is available at: www.sancilio.com.